Linked from

The 18 pages that link to Myelosuppression, each with the reason it gives.

• ImmunosuppressionRelated: When immune-cell production falls, bone-marrow suppression can weaken immune defenses.

• ChemotherapyRelated: Chemotherapy can suppress marrow cells, lowering infection-fighting white cells and other blood counts.

• AlbendazoleRelated: Rarely, extended albendazole treatment causes low blood-cell counts.

• LinezolidRelated: Linezolid can cause thrombocytopenia and other blood-count changes, especially during prolonged treatment.

• AzathioprineRelated: Azathioprine’s effects on dividing cells can suppress marrow function and lower blood-cell counts.

• ChloramphenicolRelated: Dose-related suppression is a recognized adverse effect of chloramphenicol.

• Alkylating agentRelated: Rapidly dividing marrow cells are vulnerable to many therapeutic alkylating agents.

• CyclophosphamideRelated: Cyclophosphamide suppresses marrow and can cause severe, dose-related cytopenias.

• CytarabineRelated: Bone-marrow suppression is a major consequence of cytarabine treatment and drives infection and bleeding risks.

• ZidovudineRelated: This dose-related toxicity constrained zidovudine treatment, especially in early high-dose regimens.

• PyrimethamineRelated: Pyrimethamine can impair folate-dependent blood-cell production, especially at high doses or with prolonged treatment.

• TemozolomideRelated: This is a major dose-limiting toxicity of temozolomide.

• ChlorambucilRelated: Bone-marrow suppression is a major dose-limiting toxicity of chlorambucil.

• DaunorubicinRelated: Daunorubicin suppresses marrow function, increasing risks of infection, anemia, and bleeding.

• MercaptopurineRelated: Damage to proliferating marrow cells is a major dose-limiting toxicity of mercaptopurine.

• HydroxycarbamideRelated: It is a dose-limiting effect of hydroxycarbamide and requires ongoing blood-count monitoring.

• QulastaRelated: Chemotherapy-related marrow suppression underlies the neutrophil decline Qulasta addresses.